The Role of Faecal Bile Acids in the Management of Bile Acid Diarrhoea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

112 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bile acid malabsorption (BAM), a common cause of diarrhoea, affects 1 million people in the UK, but is often misdiagnosed as irritable bowel syndrome or goes unrecognised in patients with inflammatory bowel disease.

The SeHCAT (seleno-tauro-homocholic acid) test is currently the only diagnostic test for BAM, but it is not widely available and it is also time consuming, expensive and involves exposure to radioactivity. Some clinicians give a course of blind or empirical treatment instead. The National Institute of Clinical Excellence (NICE) recognised these issues and highlighted the need for cheaper and safer tests to identify BAM.

This study will assess the accuracy of a simple, convenient and inexpensive laboratory test for the rapid diagnosis of BAM which measures bile acids in stool. This test has the potential to have a broad impact on clinical practice and patient care by enabling doctors to identify and treat patients with BAM promptly. Results from the second phase of the study will allow the assessment of the benefits of monitoring the stool test to determine whether the bile acid changes can predict the response to treatment and dosage needed for each patient.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The 8x5 Diet for Bile Acid Diarrhoea: A Feasibility Randomised Controlled Trial

NCT06259396

Bile Acid Diarrhea

RECRUITING NA

Obeticholic Acid in Bile Acid Diarrhoea

NCT01585025

Primary Bile Acid Malabsorption Secondary Bile Acid Malabsorption Chronic Diarrhoea

COMPLETED PHASE2

Serum Metabolics-based Method for Diagnosing Bile Acid Diarrhoea

NCT06548009

Bile Acid Malabsorption Bile Acid Diarrhea

COMPLETED

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

NCT05130047

Chronic Diarrhea Irritable Bowel Syndrome With Diarrhea Bile Acid Malabsorption +3 more

COMPLETED PHASE2

Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea

NCT03059537

Bile Acid Malabsorption

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The prevalence of chronic diarrhoea is 5% of the population, a third of these cases have bile acid malabsorption (BAM).

SeHCAT (seleno-tauro-homocholic acid) testing is the gold standard for BAM, and involves the ingestion of seleno-tauro-homocholic acid, which is limited to a small number of UK centres. NICE reported that although SeHCAT might benefits patients, there was a need to explore alternative technologies.

With limited access to and cost of SeHCAT, many centres use an empirical trial of bile acid sequestrants, without a diagnosis. This may not be effective as many patients are non-adherent.

This pilot study will evaluate a cheaper and simpler laboratory test, which quantitates faecal bile acids. This assay is safer, easier to use, and potentially gives a rapid diagnosis in BAM. The aim is to determine the sensitivity and specificity of this new assay. In the longitudinal phase of this study, further evaluate of faecal bile acids following bile salt sequestrant therapy, will evaluate its role in dose titration.

The following patients will be recruited (i) post-cholecystectomy; (ii) post-terminal ileal resection; or (iii) primary BAM. Patients will have SeHCAT testing and the faecal bile acid concentration will be determined.

Outcomes: The results of faecal bile acid measurement in these patients will be compared with SeHCAT to determine its sensitivity and specificity. Longitudinal follow up will determine the effect of bile salt sequestration on faecal bile acids. These results would inform the design of larger studies, allowing the evaluation of this new test in the NHS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

All patients will receive the same interventions. Single are only

Group Type EXPERIMENTAL

IDK Bile Acids

Intervention Type OTHER

colourimetric in-vitro laboratory diagnostic test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IDK Bile Acids

colourimetric in-vitro laboratory diagnostic test

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years age and over
* Willing to provide informed consent
* Post-cholecystectomy patients group (n=30; type 3 BAD)
* Post-terminal ileal resection patients with Crohn's disease group (n=30; type 1 BAD)
* D-IBS patients with normal SeHCAT retention group (n=30)
* Idiopathic bile salt diarrhoea with abnormal SeHCAT retention group (type 2 BAD) (n=30)

Exclusion Criteria

* Pregnancy/ breast feeding
* Patient participating in another trial
* Patients unable to give written consent
* Known established bile salt diarrhoea
* Recipients of antibiotics in under 4 weeks of initial trial participation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No